Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 10:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 566 matching trials from the live ClinicalTrials.gov search.
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
Phexxi
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Squamous Intraepithelial Neoplasia, Early Invasive Cervical Adenocarcinoma, Early Invasive Cervical Squamous Cell Carcinoma, High Grade Cervical Squamous Intraepithelial Neoplasia, High Grade Vaginal Intraepithelial Neoplasia, Low Grade Vaginal Intraepithelial Neoplasia, Stage I Cervical Cancer AJCC v8, Stage I Vaginal Cancer AJCC v8, Stage I Vulvar Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Vaginal Cancer AJCC v8, Stage IA Vulvar Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Vaginal Cancer AJCC v8, Stage IB Vulvar Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage II Vulvar Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Adenocarcinoma, Vulvar Adenocarcinoma, Vulvar High Grade Squamous Intraepithelial Lesion, Vulvar Intraepithelial Neoplasia, Vulvar Squamous Cell Carcinoma, Vulvar Squamous Intraepithelial Lesion
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

NCT02411916
Conditions
Postpartum Hemorrhage
Interventions
misoprostol
Biological
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older · Female only
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Jamaica, New York
Conditions
HIV Infections
Interventions
BufferGel, PRO 2000/5 Gel, Placebo gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Labor, Premature
Interventions
Vaginal progesterone gel, Placebo vaginal gel
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Conditions
Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Vaginal Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Radiation Therapy, Talazoparib
Other · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Conditions
Infertility
Interventions
DR-2011, Progesterone 8% Vaginal Gel
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Infertility
Interventions
INVOcell
Device
Lead sponsor
INVO Bioscience, Inc.
Industry
Eligibility
18 Years to 37 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Greenville, South Carolina • West Columbia, South Carolina • San Antonio, Texas + 1 more
Conditions
Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
Interventions
Conjugated Estrogens Cream, Placebo Cream
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
48 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island • Dallas, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth

NCT02913495
Conditions
Premature Birth
Interventions
Vaginal Progesterone, Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Springfield, Massachusetts • Philadelphia, Pennsylvania
Completed Phase 3 Interventional

Vaginal Infection Study 2

NCT00694928
Conditions
Vaginal Infection
Interventions
clindamycin phosphate/butoconazole nitrate, butoconazole nitrate
Drug
Lead sponsor
Lumara Health, Inc.
Industry
Eligibility
16 Years and older · Female only
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Birmingham, Alabama • Montgomery, Alabama • Jonesboro, Arkansas + 36 more
Conditions
Childbirth
Interventions
Materna Prep Device, Sham Control
Device
Lead sponsor
Materna Medical
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Mountain View, California
Conditions
Endometrial Cancer
Interventions
Multiparametric Ultrasound Imaging, The vaginal assessment score (VAS)
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

NCT01363037
Conditions
HIV Infections
Interventions
Dapivirine Vaginal Ring, Maraviroc Vaginal Ring, Placebo Vaginal Ring, Dapivirine-Maraviroc Vaginal Ring
Drug · Other
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Botswana Study of UC-781 Vaginal Microbicide

NCT00385554
Conditions
HIV Infections
Interventions
UC-781 carbomer gel, 0.1% and 0.25%
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
21 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Atlanta, Georgia • Arlington, Virginia
Conditions
Cancer
Interventions
aminocamptothecin colloidal dispersion
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Conditions
Bacterial Vaginosis
Interventions
Tinidazole
Drug
Lead sponsor
Mission Pharmacal
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Trichomonas Vaginitis
Interventions
Not listed
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Bacterial Vaginosis
Interventions
SYM-1219
Drug
Lead sponsor
Symbiomix Therapeutics
Industry
Eligibility
12 Years and older · Female only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 34 more
Conditions
Uterine Prolapse
Interventions
Laparoscopic supracervical hysterectomy with sacropexy, Vaginal hysterectomy with uterosacral colposuspension
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Atrophic Vaginitis, Breast Cancer
Interventions
Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
Conditions
Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rogers, Arkansas
Conditions
Bacteriuria
Interventions
Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 18 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bacterial Vaginosis
Interventions
SYM-1219, Placebo
Drug
Lead sponsor
Symbiomix Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Clearwater, Florida + 13 more